Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

01-11-2011 | Brief Report

Brief Report: “Allergic Symptoms” in Children with Autism Spectrum Disorders. More than Meets the Eye?

Auteurs: Asimenia Angelidou, Konstantinos-Dionysios Alysandratos, Shahrzad Asadi, Bodi Zhang, Konstantinos Francis, Magdalini Vasiadi, Dimitrios Kalogeromitros, Theoharis C. Theoharides

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 11/2011

Abstract

Many children with Autism Spectrum Disorders (ASD) have either family and/or personal history of “allergic symptomatology”, often in the absence of positive skin or RAST tests. These symptoms may suggest mast cell activation by non-allergic triggers. Moreover, children with mastocytosis or mast cell activation syndrome (MCAS), a spectrum of rare diseases characterized by increased number of activated mast cells in many organs, appear to have ASD at a rate tenfold higher (1/10 children) than that of the general population (1/100 children). Mast cell activation by allergic, infectious, environmental and stress-related triggers, especially perinatally, would release pro-inflammatory and neurotoxic molecules. We speculate these could disrupt the gut–blood–brain barriers, thus contributing to brain inflammation and ASD pathogenesis. Increased mast cell responsiveness may define at least a subgroup of ASD subjects, who could benefit from inhibition of mast cell activation.

vorige artikel Brief Report: Perceptual Load and the Autism Spectrum in Typically Developed Individuals

volgende artikel Brief Report: Excellent Agreement Between Two Brief Autism Scales (Checklist for Autism Spectrum Disorder and Social Responsiveness Scale) Completed Independently by Parents and the Autism Diagnostic Interview-Revised

Abbott, N. J. (2000). Inflammatory mediators and modulation of blood-brain barrier permeability. Cellular and Molecular Neurobiology, 20, 131–147.PubMedCrossRef

Akin, C., Valent, P., & Escribano, L. (2006). Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Current allergy and asthma reports, 6(4), 282–288.PubMedCrossRef

Akin, C., Valent, P., Metcalfe, D.D. (2010). Mast cell activation syndrome: Proposed diagnostic criteria. The Journal of Allergy and Clinical Immunology, 126(6), 1099–1104.

Angelidou, A., et al. (2010). Neurotensin is increased in serum of young children with autistic disorder. Journal of neuroinflammation, 7, 48.PubMedCrossRef

Asadullah, K., Sterry, W., & Volk, H. D. (2003). Interleukin-10 therapy–review of a new approach. Pharmacological Reviews, 55, 241–269.PubMedCrossRef

Ashwood, P., Wills, S., & Van de Water, J. (2006). The immune response in autism: a new frontier for autism research. Journal of Leukocyte Biology, 80(1), 1–15.PubMedCrossRef

Ashwood, P., et al. (2008). Decreased transforming growth factor beta1 in autism: A potential link between immune dysregulation and impairment in clinical behavioral outcomes. Journal of Neuroimmunology, 204, 149–153.PubMedCrossRef

Bakkaloglu, B., et al. (2008). Atopic features in early childhood autism. European Journal of Paediatrics Neurology, 12, 476–479.CrossRef

Bischoff, S. C. (2007). Role of mast cells in allergic and non-allergic immune responses:comparison of human and murine data. Nature Reviews Immunology, 7(2), 93–104.PubMedCrossRef

Blank, U., & Rivera, J. (2004). The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunology, 25, 266–273.CrossRef

Blaxill, M. F. (2004). What’s going on? The question of time trends in autism. Public Health Reports, 119(6), 536–551.PubMedCrossRef

Boso, M., et al. (2010). Seasonal fluctuations in problem behaviors among young adults with autism and intellectual disability. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 16(5), CR213–CR216.

Buie, T., et al. (2010). Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics, 125(Suppl 1), S1–S18.PubMedCrossRef

Cabanlit, M., Wills, S., Goines, P., Ashwood, P., & Van de Water, J. (2007). Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Annals of the New York Academy of Sciences, 1107, 92–103.PubMedCrossRef

Cao, J., et al. (2005). Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. Journal of Immunology, 174, 7665–7675.

Castells, M. (2006). Mast cell mediators in allergic inflammation and mastocytosis. Immunology and allergy clinics of North America, 26(3), 465–485.PubMedCrossRef

Chez, M. G., Dowling, T., Patel, P. B., Khanna, P., & Kominsky, M. (2007). Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatric Neurology, 36(6), 361–365.PubMedCrossRef

Chrousos, G. P. (1995). The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. New England Journal of Medicine, 332, 1351–1362.PubMedCrossRef

Conti, P., et al. (1997). Impact of Rantes and MCP-1 chemokines on in vivo basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood, 89, 4120–4127.PubMed

Corbett, B. A., Schupp, C. W., Levine, S., & Mendoza, S. (2009). Comparing cortisol, stress, and sensory sensitivity in children with autism. Autism Research, 2(1), 39–49.PubMedCrossRef

Corbett, B. A., Schupp, C. W., Simon, D., Ryan, N., & Mendoza, S. (2010). Elevated cortisol during play is associated with age and social engagement in children with autism. Molecular Autism, 1(1), 13.PubMedCrossRef

Croen, L. A., Grether, J. K., Yoshida, C. K., Odouli, R., & Van de Water, J. (2005). Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Archives of Pediatrics and Adolescent Medicine, 159(2), 151–157.PubMedCrossRef

Dirscherl, K., et al. (2010). Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. Journal of Neuroinflammation, 7(1), 3.PubMedCrossRef

Dommergues, M. A., Patkai, J., Renauld, J. C., Evrard, P., & Gressens, P. (2000). Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium. Annals of Neurology, 47(1), 54–63.PubMedCrossRef

Donelan, J., Boucher, W., Papadopoulou, N., Lytinas, M., Papaliodis, D., & Theoharides, T. C. (2006). Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proceedings of the National Academy of Sciences of the United States of America, 103, 7759–7764.PubMedCrossRef

Dunn, S. J., et al. (1993). Serotypic and genotypic characterization of human serotype 10 rotaviruses from asymptomatic neonates. Journal of Clinical Microbiology, 31(1), 165–169.PubMed

Erickson, C. A., Stigler, K. A., Corkins, M. R., Posey, D. J., Fitzgerald, J. F., & McDougle, C. J. (2005). Gastrointestinal factors in autistic disorder: a critical review. Journal of Autism and Developmental Disorders, 35(6), 713–727.PubMedCrossRef

Farhadi, A., Fields, J. Z., & Keshavarzian, A. (2007). Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World Journal of Gastroenterology, 13(22), 3027–3030.PubMed

Fombonne, E. (2009). Epidemiology of pervasive developmental disorders. Pediatric Research, 65(6), 591–598.PubMedCrossRef

Forbes, E. E., et al. (2008). IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. Journal of Experimental Medicine, 205(4), 897–913.PubMedCrossRef

Galli, S. J., Kalesnikoff, J., Grimbaldeston, M. A., Piliponsky, A. M., Williams, C. M., & Tsai, M. (2005). Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annual Review of Immunology, 23, 749–786.PubMedCrossRef

Gebhardt, T., et al. (2005). Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor beta1. Gut, 54(7), 928–934.PubMedCrossRef

Gillott, A., & Standen, P. J. (2007). Levels of anxiety and sources of stress in adults with autism. Journal of Intellectual Disabilities, 11(4), 359–370.PubMedCrossRef

Goines, P., & Van de Water, J. (2010). The immune system’s role in the biology of autism. Current Opinion in Neurology, 23(2), 111–117.PubMedCrossRef

Grandjean, P., & Landrigan, P. J. (2006). Developmental neurotoxicity of industrial chemicals. Lancet, 368(9553), 2167–2178.PubMedCrossRef

Gurney, J. G., McPheeters, M. L., & Davis, M. M. (2006). Parental report of health conditions and health care use among children with and without autism: National Survey of Children’s Health. Archives of Pediatrics and Adolescent Medicine, 160(8), 825–830.PubMedCrossRef

Herbert, M. R. (2010). Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Current Opinion in Neurology, 23(2), 103–110.PubMedCrossRef

Hertz-Picciotto, I., Park, H. Y., Dostal, M., Kocan, A., Trnovec, T., & Sram, R. (2008). Prenatal exposures to persistent and non-persistent organic compounds and effects on immune system development. Basic & Clinical Pharmacology & Toxicology, 102(2), 146–154.CrossRef

Holgate, S. T., & Polosa, R. (2008). Treatment strategies for allergy and asthma. Nature Reviews Immunology, 8(3), 218–230.PubMedCrossRef

Jang, S., Kelley, K. W., & Johnson, R. W. (2008). Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proceedings of the National Academy of Sciences of the United States of America, 105(21), 7534–7539.PubMedCrossRef

Johnson, C. P., & Myers, S. M. (2007). Identification and evaluation of children with autism spectrum disorders. Pediatrics, 120(5), 1183–1215.PubMedCrossRef

Jyonouchi, H. (2009). Food allergy and autism spectrum disorders: is there a link? Current Allergy and Asthma Reports, 9(3), 194–201.PubMedCrossRef

Jyonouchi, H. (2010). Autism spectrum disorders and allergy: observation from a pediatric allergy/immunology clinic. Expert Review of Clinical Immunology, 6(3), 397–411.PubMed

Jyonouchi, H., Geng, L., Cushing-Ruby, A., & Quraishi, H. (2008). Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. Journal of Neuroinflammation, 5, 52.PubMedCrossRef

Kandere-Grzybowska, K., et al. (2003). IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. Journal of Immunology, 171(9), 4830–4836.

Kaplan, A. P., & Greaves, M. (2009). Pathogenesis of chronic urticaria. Clinical and Experimental Allergy, 39(6), 777–787.PubMedCrossRef

Kempuraj, D., et al. (2008). Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. British Journal of Pharmacology, 155, 1076–1084.PubMedCrossRef

Kempuraj, D., et al. (2010). Mercury induces inflammatory mediator release from human mast cells. Journal of Neuroinflammation, 7(1), 20.PubMedCrossRef

Kogan, M. D., et al. (2009). Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics, 5(124), 1395–1403.CrossRef

Kraft, S., & Kinet, J. P. (2007). New developments in FcepsilonRI regulation, function and inhibition. Nature Reviews Immunology, 7(5), 365–378.PubMedCrossRef

Kulka, M., Alexopoulou, L., Flavell, R. A., & Metcalfe, D. D. (2004). Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. The Journal of Allergy and Clinical Immunology, 114(1), 174–182.PubMedCrossRef

Kwon, O., et al. (2002). Expression of cyclooxygenase-2 and pro-inflammatory cytokines induced by 2, 2’, 4, 4’, 5, 5’-hexachlorobiphenyl (PCB 153) in human mast cells requires NF-kappa B activation. Biological and Pharmaceutical Bulletin, 25(9), 1165–1168.PubMedCrossRef

Larsson, M., Weiss, B., Janson, S., Sundell, J., & Bornehag, C. G. (2009). Associations between indoor environmental factors and parental-reported autistic spectrum disorders in children 6–8 years of age. NeuroToxicology, 30(5), 822–831.PubMedCrossRef

Levy, S. E., Mandell, D. S., & Schultz, R. T. (2009). Autism. Lancet, 374(9701), 1627–1638.PubMedCrossRef

Levy, S. E., Souders, M. C., Ittenbach, R. F., Giarelli, E., Mulberg, A. E., & Pinto-Martin, J. A. (2007). Relationship of dietary intake to gastrointestinal symptoms in children with autistic spectrum disorders. Biological Psychiatry, 61(4), 492–497.PubMedCrossRef

Li, X., et al. (2009). Elevated immune response in the brain of autistic patients. Journal of Neuroimmunology, 207(1–2), 111–116.PubMedCrossRef

Magalhaes, E. S., Pinto-Mariz, F., Bastos-Pinto, S., Pontes, A. T., Prado, E. A., & Deazevedo, L. C. (2009). Immune allergic response in Asperger syndrome. Journal of Neuroimmunology, 216(1–2), 108–112.PubMedCrossRef

Matson, J. L., & Kozlowski, A. M. (2010). Autistic regression. Research in Autism Spectrum Disorders, 4, 340–345.CrossRef

Minagar, A., & Alexander, J. S. (2003). Blood-brain barrier disruption in multiple sclerosis. Multiple Sclerosis, 9(6), 540–549.PubMedCrossRef

Mostafa, G. A., Hamza, R. T., & El-Shahawi, H. H. (2008). Allergic manifestations in autistic children: Relation to disease severity. Journal of Pediatric Neurology, 6(2), 115–123.

Novembre, E., et al. (2008). Urticaria and urticaria related skin condition/disease in children. European Annals of Allergy and Clinical Immunology, 40(1), 5–13.PubMed

Rozniecki, J. J., Dimitriadou, V., Lambracht-Hall, M., Pang, X., & Theoharides, T. C. (1999). Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. Brain Research, 849, 1–15.PubMedCrossRef

Sacco, R., et al. (2010). Principal pathogenetic components and biological endophenotypes in autism spectrum disorders. Autism Research, 3(5), 237–252.PubMedCrossRef

Singer, H. S., Morris, C. M., Williams, P. N., Yoon, D. Y., Hong, J. J., & Zimmerman, A. W. (2006). Antibrain antibodies in children with autism and their unaffected siblings. Journal of Neuroimmunology, 178(1–2), 149–155.PubMedCrossRef

Slominski, A., et al. (2001). Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. Federation of American Societies for Experimental Biology, 15, 1678–1693.

Soon, D., et al. (2007). A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. Journal of Neurology, 254(3), 306–314.PubMedCrossRef

Stefanatos, G. A. (2008). Regression in autistic spectrum disorders. Neuropsychology Review, 18(4), 305–319.PubMedCrossRef

Stone, L. A., et al. (1995). Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and age. Neurology, 45, 1122–1126.PubMed

Theoharides, T. C. (2009). Autism spectrum disorders and mastocytosis. International Journal of Immunopathology and Pharmacology, 22(4), 859–865.PubMed

Theoharides, T. C., & Cochrane, D. E. (2004). Critical role of mast cells in inflammatory diseases and the effect of acute stress. Journal of Neuroimmunology, 146, 1–12.PubMedCrossRef

Theoharides, T. C., Doyle, R., Francis, K., Conti, P., & Kalogeromitros, D. (2008). Novel therapeutic targets for autism. Trends in Pharmacological Sciences, 29(8), 375–382.PubMedCrossRef

Theoharides, T. C., & Kalogeromitros, D. (2006). The critical role of mast cell in allergy and inflammation. Annals of the New York Academy of Sciences, 1088, 78–99.PubMedCrossRef

Theoharides, T. C., Kempuraj, D., & Redwood, L. (2009). Autism: an emerging ‘neuroimmune disorder’ in search of therapy. Experimental Opinion on Pharmacotherapy, 10(13), 2127–2143.CrossRef

Theoharides, T. C., Kempuraj, D., Tagen, M., Conti, P., & Kalogeromitros, D. (2007). Differential release of mast cell mediators and the pathogenesis of inflammation. Immunological Reviews, 217, 65–78.PubMedCrossRef

Theoharides, T. C., & Konstantinidou, A. (2007). Corticotropin-releasing hormone and the blood-brain-barrier. Frontiers in Bioscience, 12, 1615–1628.PubMedCrossRef

Valent, P., et al. (2001). Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukemia Research, 25, 603–625.PubMedCrossRef

Varadaradjalou, S., et al. (2003). Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. European Journal of Immunology, 33, 899–906.PubMedCrossRef

Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005). Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals of Neurology, 57(1), 67–81.PubMedCrossRef

Vojdani, A., Campbell, A. W., Anyanwu, E., Kashanian, A., Bock, K., & Vojdani, E. (2002). Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. Journal of Neuroimmunology, 129(1–2), 168–177.PubMedCrossRef

Weiss, L. A., Arking, D. E., Daly, M. J., & Chakravarti, A. (2009). A genome-wide linkage and association scan reveals novel loci for autism. Nature, 461(7265), 802–808.PubMedCrossRef

Wills, S., Cabanlit, M., Bennett, J., Ashwood, P., Amaral, D. G., & Van de Water, J. (2008). Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders. Brain, Behavior, and Immunology, 23, 64–74.CrossRef

Young, H. A., Geier, D. A., & Geier, M. R. (2008). Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. Journal of the Neurological Sciences, 271(1–2), 110–118.PubMedCrossRef

Zappella, M. (2010). Autistic regression with and without EEG abnormalities followed by favourable outcome. Brain and Development, 32(9), 739–745.PubMedCrossRef

Titel: Brief Report: “Allergic Symptoms” in Children with Autism Spectrum Disorders. More than Meets the Eye?
Auteurs: Asimenia Angelidou
Konstantinos-Dionysios Alysandratos
Shahrzad Asadi
Bodi Zhang
Konstantinos Francis
Magdalini Vasiadi
Dimitrios Kalogeromitros
Theoharis C. Theoharides
Publicatiedatum: 01-11-2011
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 11/2011
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-010-1171-z

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 11/2011

Investigating Multitasking in High-Functioning Adolescents with Autism Spectrum Disorders Using the Virtual Errands Task

Is Neonatal Jaundice Associated with Autism Spectrum Disorders: A Systematic Review

Reliability of Eye Tracking and Pupillometry Measures in Individuals with Fragile X Syndrome

G. Firth, R. Berry and C. Irvine: Understanding Intensive Interaction: Context and Concepts for Professionals and Families

Diminished Sensitivity to Sad Facial Expressions in High Functioning Autism Spectrum Disorders is Associated with Symptomatology and Adaptive Functioning

Writing, Asperger Syndrome and Theory of Mind